Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease

Savina M L Aversa, Luigi Salvagno, Mariella Sorarù, Renzo Mazzarotto, Caterina Boso, Fernando Gaion, Vanna Chiarion-Sileni, Giuseppe De Franchis, Adolfo G. Favaretto, Gino Crivellari, Giuseppe Luigi Banna, Guido Sotti, Silvio Monfardini

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Since September 1996, 48 untreated patients with bulky or advanced-stage Hodgkin's disease received the 12-week Stanford V chemotherapy regimen followed by consolidation radiotherapy at a dose of 36 Gy to bulky mediastinal disease and 30.6 Gy to the initial sites of disease ≥3 cm in transverse diameter. After the combined therapy, 46 of 48 (96%) achieved complete remissions. With a median follow-up of 48 months, the 5-year overall survival was 95% and freedom from progression 86%. There were no treatment-related deaths. All but one premenopausal female patient (who received pelvic and inguinal irradiation) recovered normal menses. Until now no case of secondary leukemia or myelodysplasia was observed. Our results confirm that the Stanford V regimen with consolidation radiotherapy is safe and effective in patients with bulky or advanced-stage Hodgkin's disease, achieving very high remission and overall 5-year survival rates. Longer follow-up is necessary to evaluate the extent of all complications.

Original languageEnglish
Pages (from-to)141-147
Number of pages7
JournalActa Haematologica
Volume112
Issue number3
DOIs
Publication statusPublished - 2004

Fingerprint

Hodgkin Disease
Radiotherapy
Mediastinal Diseases
Menstruation
Groin
Leukemia
Therapeutics
Survival Rate
Drug Therapy
Survival

Keywords

  • Advanced stages
  • Combined modality therapy
  • Hodgkin's disease

ASJC Scopus subject areas

  • Hematology

Cite this

Aversa, S. M. L., Salvagno, L., Sorarù, M., Mazzarotto, R., Boso, C., Gaion, F., ... Monfardini, S. (2004). Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease. Acta Haematologica, 112(3), 141-147. https://doi.org/10.1159/000079725

Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease. / Aversa, Savina M L; Salvagno, Luigi; Sorarù, Mariella; Mazzarotto, Renzo; Boso, Caterina; Gaion, Fernando; Chiarion-Sileni, Vanna; De Franchis, Giuseppe; Favaretto, Adolfo G.; Crivellari, Gino; Banna, Giuseppe Luigi; Sotti, Guido; Monfardini, Silvio.

In: Acta Haematologica, Vol. 112, No. 3, 2004, p. 141-147.

Research output: Contribution to journalArticle

Aversa, SML, Salvagno, L, Sorarù, M, Mazzarotto, R, Boso, C, Gaion, F, Chiarion-Sileni, V, De Franchis, G, Favaretto, AG, Crivellari, G, Banna, GL, Sotti, G & Monfardini, S 2004, 'Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease', Acta Haematologica, vol. 112, no. 3, pp. 141-147. https://doi.org/10.1159/000079725
Aversa, Savina M L ; Salvagno, Luigi ; Sorarù, Mariella ; Mazzarotto, Renzo ; Boso, Caterina ; Gaion, Fernando ; Chiarion-Sileni, Vanna ; De Franchis, Giuseppe ; Favaretto, Adolfo G. ; Crivellari, Gino ; Banna, Giuseppe Luigi ; Sotti, Guido ; Monfardini, Silvio. / Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease. In: Acta Haematologica. 2004 ; Vol. 112, No. 3. pp. 141-147.
@article{98e0f7596df54f3ca8f8720b839b39c3,
title = "Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease",
abstract = "Since September 1996, 48 untreated patients with bulky or advanced-stage Hodgkin's disease received the 12-week Stanford V chemotherapy regimen followed by consolidation radiotherapy at a dose of 36 Gy to bulky mediastinal disease and 30.6 Gy to the initial sites of disease ≥3 cm in transverse diameter. After the combined therapy, 46 of 48 (96{\%}) achieved complete remissions. With a median follow-up of 48 months, the 5-year overall survival was 95{\%} and freedom from progression 86{\%}. There were no treatment-related deaths. All but one premenopausal female patient (who received pelvic and inguinal irradiation) recovered normal menses. Until now no case of secondary leukemia or myelodysplasia was observed. Our results confirm that the Stanford V regimen with consolidation radiotherapy is safe and effective in patients with bulky or advanced-stage Hodgkin's disease, achieving very high remission and overall 5-year survival rates. Longer follow-up is necessary to evaluate the extent of all complications.",
keywords = "Advanced stages, Combined modality therapy, Hodgkin's disease",
author = "Aversa, {Savina M L} and Luigi Salvagno and Mariella Sorar{\`u} and Renzo Mazzarotto and Caterina Boso and Fernando Gaion and Vanna Chiarion-Sileni and {De Franchis}, Giuseppe and Favaretto, {Adolfo G.} and Gino Crivellari and Banna, {Giuseppe Luigi} and Guido Sotti and Silvio Monfardini",
year = "2004",
doi = "10.1159/000079725",
language = "English",
volume = "112",
pages = "141--147",
journal = "Acta Haematologica",
issn = "0001-5792",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease

AU - Aversa, Savina M L

AU - Salvagno, Luigi

AU - Sorarù, Mariella

AU - Mazzarotto, Renzo

AU - Boso, Caterina

AU - Gaion, Fernando

AU - Chiarion-Sileni, Vanna

AU - De Franchis, Giuseppe

AU - Favaretto, Adolfo G.

AU - Crivellari, Gino

AU - Banna, Giuseppe Luigi

AU - Sotti, Guido

AU - Monfardini, Silvio

PY - 2004

Y1 - 2004

N2 - Since September 1996, 48 untreated patients with bulky or advanced-stage Hodgkin's disease received the 12-week Stanford V chemotherapy regimen followed by consolidation radiotherapy at a dose of 36 Gy to bulky mediastinal disease and 30.6 Gy to the initial sites of disease ≥3 cm in transverse diameter. After the combined therapy, 46 of 48 (96%) achieved complete remissions. With a median follow-up of 48 months, the 5-year overall survival was 95% and freedom from progression 86%. There were no treatment-related deaths. All but one premenopausal female patient (who received pelvic and inguinal irradiation) recovered normal menses. Until now no case of secondary leukemia or myelodysplasia was observed. Our results confirm that the Stanford V regimen with consolidation radiotherapy is safe and effective in patients with bulky or advanced-stage Hodgkin's disease, achieving very high remission and overall 5-year survival rates. Longer follow-up is necessary to evaluate the extent of all complications.

AB - Since September 1996, 48 untreated patients with bulky or advanced-stage Hodgkin's disease received the 12-week Stanford V chemotherapy regimen followed by consolidation radiotherapy at a dose of 36 Gy to bulky mediastinal disease and 30.6 Gy to the initial sites of disease ≥3 cm in transverse diameter. After the combined therapy, 46 of 48 (96%) achieved complete remissions. With a median follow-up of 48 months, the 5-year overall survival was 95% and freedom from progression 86%. There were no treatment-related deaths. All but one premenopausal female patient (who received pelvic and inguinal irradiation) recovered normal menses. Until now no case of secondary leukemia or myelodysplasia was observed. Our results confirm that the Stanford V regimen with consolidation radiotherapy is safe and effective in patients with bulky or advanced-stage Hodgkin's disease, achieving very high remission and overall 5-year survival rates. Longer follow-up is necessary to evaluate the extent of all complications.

KW - Advanced stages

KW - Combined modality therapy

KW - Hodgkin's disease

UR - http://www.scopus.com/inward/record.url?scp=4644225088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644225088&partnerID=8YFLogxK

U2 - 10.1159/000079725

DO - 10.1159/000079725

M3 - Article

VL - 112

SP - 141

EP - 147

JO - Acta Haematologica

JF - Acta Haematologica

SN - 0001-5792

IS - 3

ER -